Compare AbbVie Inc (ABBV) vs Barrick Gold Corp (B) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbbVie Inc vs Barrick Gold Corp — how do they compare? AbbVie Inc trades at $252.9 (market cap $449.91B), while Barrick Gold Corp trades at $35.63 (market cap $61.76B). The key difference: AbbVie Inc is far larger — about 7.3× Barrick Gold Corp's market cap, and AbbVie Inc pays the higher dividend (2.72%). Which is the better fit depends on your goals.
| ABBV | B | |
|---|---|---|
Market Cap | $449.91B | $61.76B |
Sector | Health | Basic Materials |
52-Week High | $261.07 | $52.97 |
52-Week Low | $184.85 | $20.73 |
Enterprise Value | $513.38B | $59.35B |
Dividend Yield | 2.72% | 1.9% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $252.92, down 0.72% on the day, with strong technical support at $251 and resistance at $258. The stock shows bullish momentum with recent earnings beats and a consensus analyst price target of $266.33. Revenue grew to $61.16B in 2025, though net margins compressed to 5.79%. Key growth drivers include Skyrizi and Rinvoq offsetting Humira declines, supported by positive Phase 2 data for ELAHERE in ovarian cancer (PRNewsWire, 2026-04-12).
Outlook remains positive with immunology portfolio strength and dividend growth, but risks include patent cliffs in the 2030s and high debt levels. Institutional buying and 68% analyst buy ratings suggest confidence, though valuation multiples like P/E of 124.83 warrant caution. Near-term catalysts include Q2 2026 earnings expected at $3.79 EPS.
Barrick Mining (B) trades at $36.86, down 3.55% over 24 hours, with technical indicators signaling a bearish trend. The company demonstrates strong fundamentals with a P/E of 10.07, net income margin of 32.14%, and consistent earnings beats in recent quarters. Revenue surged to $17.0B in 2025, up from $12.9B in 2024, while cash flow from operations improved to $7.7B. A dividend of $0.18 per share is scheduled for payment on June 15, 2026.
The stock presents a value opportunity with a consensus price target of $51.33, implying 39% upside, supported by 68% analyst buy ratings. Risks include gold price volatility and operational execution challenges. Strong cash flow generation and low debt levels provide a solid foundation for growth, though near-term technical weakness may persist.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About Barrick Gold Corp
Barrick Gold Corp is one of the world's largest gold producers, operating mines in North America, South America, Australia, and Africa. The company segments consist of nine gold mines namely Carlin, Cortez, Turquoise Ridge, Pueblo Viejo, Loulo-Gounkoto, Kibali, Veladero, North Mara, and Bulyanhulu. It generates maximum revenue from the Carlin mine segment. Geographically, it derives a majority of revenue from the United States.
Read more on B →
